Half-year report · HY
2342.TEDINET S100WYWR
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥13.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥6.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥71m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | −¥111m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥83m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥320m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥157m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥57m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥195m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥30m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥182m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥11m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | −¥185m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥9.6bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥9.6bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥10.6bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.8bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥4.7bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥4.9bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥4.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.8bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.2bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.5bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥569m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥94m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥421m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥36m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥288m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥175m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥261m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥265m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥379m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥1.77 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-65.51 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-10.97 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 49.8% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.7% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.5% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥98m |
| Drug Discovery Support Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥938m |
| Drug Discovery Support Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥935m |
| Drug Discovery Support Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3m |
| Drug Discovery Support Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥75m |
| Investments And Consulting Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.3bn |
| Investments And Consulting Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.3bn |
| Investments And Consulting Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥62,000 |
| Investments And Consulting Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥245m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥170m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥114m |
| Drug Discovery Support Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥806m |
| Drug Discovery Support Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥803m |
| Drug Discovery Support Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3m |
| Drug Discovery Support Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥189m |
| Investments And Consulting Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| Investments And Consulting Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| Investments And Consulting Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥45,000 |
| Investments And Consulting Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥192m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥3m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 508
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents | Prior2YearInstant | 2466101000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2541738000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 2244975000 | JPY |
| Cash and cash equivalents | InterimInstant | 2198191000 | JPY |
| Salaries and allowances sga | Prior1InterimDuration | 299265000 | JPY |
| Salaries and allowances sga | InterimDuration | 281278000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 2171000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 3055000 | JPY |
| Provision for bonuses sga | Prior1InterimDuration | 43424000 | JPY |
| Provision for bonuses sga | InterimDuration | 42688000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 803128000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 5508752000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 6311881000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 6311881000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 3000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 45000 | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 3045000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -3045000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 806128000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 5508798000 | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 6314926000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | -3045000 | JPY |
| Net sales | Prior1InterimDuration | 6311881000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | -188669000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 191717000 | JPY |
| Operating income | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 3048000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | -113817000 | JPY |
| Operating income | Prior1InterimDuration | -110769000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 934711000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 5290141000 | JPY |
| Revenues from external customers | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 6224853000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 6224853000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 3000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 62000 | JPY |
| Transactions with other segments | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 3062000 | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | -3062000 | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 937711000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 5290204000 | JPY |
| Net sales | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 6227916000 | JPY |
| Net sales | InterimDuration_ReconcilingItemsMember | -3062000 | JPY |
| Net sales | InterimDuration | 6224853000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | -75224000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember | 245102000 | JPY |
| Operating income | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 169878000 | JPY |
| Operating income | InterimDuration_ReconcilingItemsMember | -98472000 | JPY |
| Operating income | InterimDuration | 71405000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |